TriSalus Life Sciences (TLSI) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Exagen (XGN) over the past year, losing 14.8% versus a loss of 25.6%. Over five years, XGN leads with a -35.3% price change compared with -58.3% for TLSI. TriSalus Life Sciences is the larger company by market cap ($254.3 million vs $197.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSI | XGN |
|---|---|---|
| Share price | $4.13 | $8.17 |
| Market cap | $254.30M | $197.92M |
| 1-day change | -2.82% | -1.57% |
| YTD return | -40.83% | +34.38% |
| 1-year return | -14.85% | -25.59% |
| 5-year return | -58.28% | -35.31% |
| EPS (TTM) | $-1.22 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $12.23 |
| 52-week low | $2.20 | $2.59 |
| Distance from 52-week high | -48.05% | -33.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +151.82% | +24.11% |
| Average volume | 275.38K | 328.42K |
| Shares outstanding | 61.57M | 24.23M |
| Employees | 102 | 216 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSI has outperformed XGN by 10.7 percentage points over the past year.
- The two companies sit in different sectors: TriSalus Life Sciences in Healthcare and Exagen in Health Care.
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Healthcare · Medical Devices · 102 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
TLSI vs XGN FAQ
Which is bigger, TriSalus Life Sciences or Exagen?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $254.30M compared with $197.92M for Exagen (XGN).
Which stock has performed better over the past year, TLSI or XGN?
TLSI returned -14.85% over the past 12 months, compared with -25.59% for XGN (price return, excluding dividends). Past performance does not predict future results.
Are TriSalus Life Sciences and Exagen in the same industry?
No. TriSalus Life Sciences is in the Healthcare sector, while Exagen is in Health Care.